NGM

NGM Biopharmaceuticals, Inc. (NGM) | Rumor.io

NGM Biopharmaceuticals

NGM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NGM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% +0

Feb 27

NGM Biopharmaceuticals, Inc. has been acquired by Column Group, LP affiliates, with an accepted offer to take the company private at $1.55 per share.
The stock price traded above the buyout price on the same day, with some investors expressing outrage and calling for legal action.
Analysts have questioned the strategic decision and the low price of the acquisition, with one analyst calling it "mistimed" and others speculating about potential fake-outs or manipulations.

Generated by AI

Sentiment

Of the messages about NGM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0%	12.5%
Bearish	100%	100%	100%	87.5%

Bullish· Feb 22

$NGM has shown significant volume increases, with 1.9 million shares traded on Thursday, indicating strong investor interest.
The company's chart is comparable to $ARQT, suggesting a potential multi-month breakout after consolidation.
$NGM's stock has a high likelihood of reaching $2.20, with some traders aiming for a price of $4 or higher.

Bearish· Oct 17

$NGM's recent 70% price drop is largely due to the failure of its lead product NGM621 in a Phase 2 clinical trial for geographic atrophy.
NGM Biopharmaceuticals' pipeline, which was previously seen as a positive factor, is now being discounted by investors, with the stock trading at cash value despite its other products.
NGM's market capitalization has been significantly reduced, with over $600 million in value vaporized, likely due to short sellers who were caught off guard by the company's announcement.

Generated by AI

Topics

Of the messages about NGM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	50%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	50%
Technical Analysis	—	—	—	0%

Feb 26

NGM Biopharmaceuticals, Inc. ($NGM) has entered into a definitive agreement and plan of merger with affiliates of The Column Group, LP, with stockholders set to receive $1.55 per share in cash, an 80% premium over the closing share price.
The all-cash tender offer values the company at $135 million on a fully diluted basis, with the acquisition expected to close in the second quarter of 2024, resulting in $NGM becoming a privately held company.
NGM Bio's stock price has declined significantly, down 67% in the past 12 months, and has been halted for trading on February 26, 2024, due to the news of the acquisition.

Generated by AI

Community

Of the messages about NGM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Regulars· Feb 26

NGM Biopharmaceuticals has entered into a definitive agreement and plan of merger with The Column Group, LP, with stockholders set to receive $1.55 per share in cash.
The acquisition is expected to close in the second quarter of 2024, resulting in NGM becoming a privately held company with a total equity value of $135 million on a fully diluted basis.
The merger has led to a significant decline in NGM's stock price, with the company trading 19.90% lower on high volume, despite the news of the merger and the potential benefits it could bring to the company.

Newcomers· Jan 2

$NGM is up 50% after Column Group announced a buyout bid to take the company private.
The deal has a potential connection to $SRZN, as Column Group owns a 30% stake in that company.
Column Group is a large holder of $NGM with a significant amount of cash, which may be used to finance the buyout.

Generated by AI

Also Discussed

Investors talking about NGM also mention

#	Name	Attention
1	Galecto Inc.GLTO	0%0
2	ETNB - 89bio, Inc.	——
3	SILK - Silk Road Medical, Inc	——
4	Akash NetworkAKT	0.01%-0.01
5	Passage Bio Inc.PASG	0%0
6	AtomOneATONE	0%+0
7	Invesco CurrencyShares Swiss Franc TrustFXF	0%0
8	AKRO - Akero Therapeutics, Inc.	——
9	Atomera IncATOM	0%+0
10	TopBuild CorpBLD	0%new